DISCLAIMER: This link was displayed at 03:46:37 20/04/2024 and expires on 25/04/2024 if printed.

Go to http://testguide.adhb.govt.nz/EGuide/ for more information.

Specimen Collection

Paired sera should be obtained wherever possible:

(a) acute sample - as early as possible in the illness, and
(b) convalescent sample 2 - 3 weeks after onset.

3.5 mL SST Serum (Preferred)
4 mL Plain Serum
500 uL Microsample Serum
Reference Intervals

Assay measuring range: 7.00-0.01 IU/mL

Levels of tetanus antibody 0.1 IU/mL or greater are indicative of immunity to tetanus.

Uncertainty of Measurement:   12%

Turnaround Time: Between 2 weeks and 3 weeks
Diagnostic Use and Interpretation

Positive results in neonatal specimens (£ 6 months of age) must be interpreted with caution due to passive transfer of maternal IgG

Results may be used to aid a diagnosis of immunodeficiency.

Anti-tetanus toxoid antibodies are raised in response to vaccination with tetanus toxoid protein. This assay is intended for the in-vitro measurement of specific IgG antibodies against tetanus toxoid present in serum in order to determine protective status pre and post vaccination. Protective levels are cited as between 0.01-0.15 IU/mL. In our setting, the assay is used in conjunction with vaccine challenge results from Hib, HBsAg, pneumococcus and diphtheria toxoid to assist in the determination of the probable type of immunodeficiency.

Reference

Binding Site insert for Tetanus Toxoid IgG EIA kit.

Contact Information

For further information contact the laboratory, (09) 307 4949 ext 22103 or:
Associate Professor Rohan Ameratunga , Immunopathologist: Locator 93-5724,  

Dr Richard Steele , or  The LabPLUS Immunology Team

Last updated at 13:35:45 22/02/2019